TheStreet downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to Hold in a statement released earlier today.
- Updated: September 16, 2016
Having a price of $51.56, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) traded 0.31% lower on the day. The last stock price is down 3.11% relative to the two hundred day average, compared with the S&P 500 which has decreased -0.01% over the same period. Teva Pharmaceutical Industries Ltd (ADR) has logged a 50-day average of $52.42 and 200-day moving average of $53.40. 4,650,728 shares of TEVA were exchanged, down from ann avg. volume of 5,895,710
TheStreet has downgraded Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) to Hold in a statement released Friday September 9 2016.
In addition to TheStreet reporting it’s target price, a total of 22 brokers have released a research note on Teva Pharmaceutical Industries Ltd (ADR). The one year target stock price is $72.82 with 10 analysts rating the company a strong buy, nine analysts rating the stock a buy, six analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 analysts rating the company as sell.
With a market capitalization of $0.0, Teva Pharmaceutical Industries Ltd (ADR) has a price-earnings of 35 with a one-year low of $48.01 and a 52 week high of $66.55.
General Information About Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1, 000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women’s health portfolio includes ParaGard, and Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.